Curis Inc (CRIS) stock
CRISNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.45−0.13 (-22.18%)
Close on Nov 13, 2026Market cap $930.08KP/E –Yield –
Curis r&d expenses
Research and development expenses are spending on new products and technology.
Curis's R&D Expenses for the twelve months ending Sep 30, 2026 was $24.58M, down 21.7% year over year. For fiscal 2025 it was $28.25M, down 26.7% from the year before. Over ten years it grew 0.6% a year on average. The highest annual figure on record is $45.10M in fiscal 2017.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.25M | -26.7% |
| FY2024 | Dec 31, 2024 | $38.56M | -2.4% |
| FY2023 | Dec 31, 2023 | $39.50M | -8.7% |
| FY2022 | Dec 31, 2022 | $43.28M | +24.1% |
| FY2021 | Dec 31, 2021 | $34.88M | +51.2% |
| FY2020 | Dec 31, 2020 | $23.07M | +3.4% |
| FY2019 | Dec 31, 2019 | $22.30M | -8.6% |
| FY2018 | Dec 31, 2018 | $24.41M | -45.9% |
| FY2017 | Dec 31, 2017 | $45.10M | +150.5% |
| FY2016 | Dec 31, 2016 | $18.00M | -32.6% |
| FY2015 | Dec 31, 2015 | $26.70M | +95.5% |
| FY2014 | Dec 31, 2014 | $13.66M | +5.7% |
| FY2013 | Dec 31, 2013 | $12.93M | -16.6% |
| FY2012 | Dec 31, 2012 | $15.49M | +13.1% |
| FY2011 | Dec 31, 2011 | $13.69M | +20.4% |
| FY2010 | Dec 31, 2010 | $11.37M | +14.5% |
| FY2009 | Dec 31, 2009 | $9.93M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $5.60M | -13.0% |
| Q2 FY2026 | Jun 30, 2026 | $6.71M | -10.0% |
| Q1 FY2026 | Mar 31, 2026 | $6.45M | -24.5% |
| Q4 FY2025 | Dec 31, 2025 | $5.83M | -35.0% |
| Q3 FY2025 | Sep 30, 2025 | $6.43M | -33.8% |
| Q2 FY2025 | Jun 30, 2025 | $7.46M | -27.3% |
| Q1 FY2025 | Mar 31, 2025 | $8.54M | -11.2% |
| Q4 FY2024 | Dec 31, 2024 | $8.97M | -10.0% |
| Q3 FY2024 | Sep 30, 2024 | $9.72M | -6.3% |
| Q2 FY2024 | Jun 30, 2024 | $10.25M | +2.4% |
| Q1 FY2024 | Mar 31, 2024 | $9.62M | +5.2% |
| Q4 FY2023 | Dec 31, 2023 | $9.96M | +14.4% |
| Q3 FY2023 | Sep 30, 2023 | $10.38M | -4.0% |
| Q2 FY2023 | Jun 30, 2023 | $10.01M | -18.8% |
| Q1 FY2023 | Mar 31, 2023 | $9.14M | -20.1% |
| Q4 FY2022 | Dec 31, 2022 | $8.71M | -19.2% |
| Q3 FY2022 | Sep 30, 2022 | $10.81M | +25.7% |
| Q2 FY2022 | Jun 30, 2022 | $12.32M | +40.8% |
| Q1 FY2022 | Mar 31, 2022 | $11.44M | +69.2% |
| Q4 FY2021 | Dec 31, 2021 | $10.77M | +92.0% |
| Q3 FY2021 | Sep 30, 2021 | $8.60M | +82.8% |
| Q2 FY2021 | Jun 30, 2021 | $8.75M | +65.7% |
| Q1 FY2021 | Mar 31, 2021 | $6.76M | -9.6% |
| Q4 FY2020 | Dec 31, 2020 | $5.61M | -24.8% |
| Q3 FY2020 | Sep 30, 2020 | $4.71M | -8.6% |
| Q2 FY2020 | Jun 30, 2020 | $5.28M | -6.0% |
| Q1 FY2020 | Mar 31, 2020 | $7.47M | +83.4% |
| Q4 FY2019 | Dec 31, 2019 | $7.46M | +58.3% |
| Q3 FY2019 | Sep 30, 2019 | $5.15M | +3.3% |
| Q2 FY2019 | Jun 30, 2019 | $5.62M | -12.9% |
| Q1 FY2019 | Mar 31, 2019 | $4.07M | -50.7% |
| Q4 FY2018 | Dec 31, 2018 | $4.71M | -31.9% |
| Q3 FY2018 | Sep 30, 2018 | $4.98M | -62.8% |
| Q2 FY2018 | Jun 30, 2018 | $6.45M | -42.7% |
| Q1 FY2018 | Mar 31, 2018 | $8.27M | -39.0% |
| Q4 FY2017 | Dec 31, 2017 | $6.92M | -24.5% |
| Q3 FY2017 | Sep 30, 2017 | $13.38M | – |
| Q2 FY2017 | Jun 30, 2017 | $11.26M | – |
| Q1 FY2017 | Mar 31, 2017 | $13.54M | – |
| Q4 FY2016 | Dec 31, 2016 | $9.16M | – |
See a number that looks wrong?